JOHNSON JOHN 4

4 · Xeris Biopharma Holdings, Inc. · Filed Jun 5, 2026

AI-generated summary of this filing

Updated Jun 5, 2026

Xeris (XERS) Director John Johnson Sells Shares, Receives RSUs & Options

What Happened

John Johnson, a director of Xeris Biopharma (XERS), sold 15,000 shares in an open-market transaction on June 4, 2026 for a weighted average price of $6.09, receiving $91,422. On the same day he was granted 24,193 restricted stock units (RSUs) (no cash cost) and 32,996 stock options (derivative grant) recorded with a value of $202,925 and a reported per-share price of $6.15.
The sale is typically viewed as routine trading, while the RSUs and option grant are equity compensation awards tied to future vesting.

Key Details

Transaction date: June 4, 2026; Form 4 filed June 5, 2026 (timely).
Sale: 15,000 shares disposed; weighted average sale price $6.09; total proceeds $91,422. (Footnote: shares sold across prices from $5.97 to $6.17; holder will provide detailed breakdown on request.)
Grants: 24,193 RSUs (acquired at $0.00) and 32,996 stock options (derivative grant) shown with a value of $202,925 and price $6.15.
Vesting/conditions: Both the RSUs and options vest in full upon the earlier of June 4, 2026 or the date of the company’s next annual meeting, subject to continued service. (See footnotes for details.)
Rule 10b5-1 plan: The sale was made under a pre-established Rule 10b5-1 trading plan adopted by the reporting person on Aug 13, 2025.
Shares owned after transaction: Not specified in the excerpt provided.

Context

RSUs represent a contingent right to receive shares upon vesting; these are compensation awards and do not represent an immediate purchase or market bet. The option grant is a derivative award that will only deliver value if the stock exceeds the option terms upon exercise; the filing does not indicate any immediate exercise or sale of those option shares.
The open-market sale being executed under a 10b5-1 plan suggests it was pre-scheduled rather than a discretionary trade made that day.

Form 4

Period: 2026-06-04

Director

Transactions

Sale
Common Stock
[F1][F2]
2026-06-04$6.09/sh−15,000$91,422→ 683,083 total
Award
Common Stock
[F3]
2026-06-04+24,193→ 707,276 total
Award
Stock Option (Right to Buy)
[F4]
2026-06-04$6.15/sh+32,996$202,925→ 32,996 total
Exercise: $6.15Exp: 2036-06-04→ Common Stock (32,996 underlying)

Footnotes (4)

[F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F3]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
[F4]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Signature

/s/ Beth Hecht, Attorney-in-Fact|2026-06-05

1 file